Mounjaro and Zepbound support weight loss and significantly lower the risk of type 2 diabetes, thanks to the active ingredient tirzepatide. Research by Eli Lilly, the manufacturer of these medications, shows that tirzepatide can reduce the risk of type 2 diabetes by up to 94% in adults with prediabetes who are overweight.
The study, named SURMOUNT-1, included over 1032 adults who used tirzepatide for three years. Participants who received a 15 mg injection lost an average of 22.9% of their body weight, compared to just 2.1% in those not taking tirzepatide.
Dr. Jeff Emmick, one of the researchers, explains that obesity is a chronic condition affecting nearly 900 million adults globally. He highlights that tirzepatide not only supports sustainable weight loss, but also lowers the risk of developing type 2 diabetes. Excess abdominal fat often increases insulin resistance, making it harder to regulate blood sugar levels.
The study also examined what happens after stopping tirzepatide. Seventeen weeks post-treatment, participants began regaining weight, and their diabetes risk increased. However, the risk remained 88% lower than in those who never used tirzepatide.
Do you have questions about using Mounjaro or other weight management solutions? Want to know if it’s right for you? Contact Elysee and click here to schedule a free consultation!
Source: Investor Lilly
